-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Insulet, Raises Price Target to $171

Benzinga·11/06/2026 00:41:25
Listen to the news
UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $171.